FDMT Projected Dividend Yield
4D Molecular Therapeutics Inc ( NASDAQ : FDMT )4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on treating ophthalmology and pulmonology diseases. It has five product candidates in clinical trials: 4D-150 for wet age-related macular degeneration and diabetic macular edema, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for X-linked retinitis pigmentosa, and 4D-110 for choroideremia. Additionally, it has two preclinical candidates: 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. 21 YEAR PERFORMANCE RESULTS |
FDMT Dividend History Detail FDMT Dividend News FDMT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |